Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas. Read more about Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas.
Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. Read more about Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review.
Lung cancer in never smokers: Distinct population-based patterns by age, sex, and race/ethnicity. Read more about Lung cancer in never smokers: Distinct population-based patterns by age, sex, and race/ethnicity.
Adjust, don't avoid: The need for risk-based CT screening in nonsmoking populations. Read more about Adjust, don't avoid: The need for risk-based CT screening in nonsmoking populations.
Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Read more about Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. Read more about Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Read more about Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Read more about Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
Real-world lung cancer screening decision-making: Barriers and facilitators. Read more about Real-world lung cancer screening decision-making: Barriers and facilitators.
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Read more about Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
